Latest Research & Reports

This report provides an overview of all the type 1 diabetes research projects currently active in human trials registered with the US FDA.

JDRF’s 2021 Fiscal Year endured the full force of COVID-19, stretching from July 2020 to June 2021. During this period, many organizations saw a contraction in revenue and, in response, reduced expenses substantially. JDRF cut expenses but, at the same time, surprisingly, experienced near record-high income.

This morning, Vertex Pharmaceuticals announced that it will acquire the private biotech startup ViaCyte for $320 million in cash. The deal will bring together two companies that have been competing to develop a Practical Cure for T1D.

Vertex Pharmaceuticals announced on Tuesday that the FDA will allow the company to continue its human trial of VX-880, the novel line of insulin-producing cells derived from stem cells.

Last weekend, The Human Trial, a must-see film for anyone interested in the effort to cure type 1 diabetes, opened in select cities across the United States.

This report will analyze the American Diabetes Association (ADA) Fiscal Year 2021 Audited Financial Statements, which cover a period from January 1, 2021 to December 31, 2021.